Molecular Partners AG - MOLN STOCK NEWS

Molecular Partners has revealed promising preclinical data for MP0621, their first Switch-DARPin candidate, at the European Hematology Association 2024. MP0621 targets cKit-positive cells and conditionally blocks CD47 to facilitate hematopoietic stem cell transplantation (HSCT) in acute myeloid leukemia (AML) patients. The candidate showed selective cell killing and minimal systemic side effects in vivo, validating the Switch-DARPin concept. Preclinical studies demonstrated effective cKit+ cell depletion and a pharmacokinetic profile suitable for HSCT therapy. Phase 1 clinical trials for MP0621 are scheduled for 2025.

Molecular Partners and Orano Med have presented promising preclinical data for their Radio-DARPin Therapy (RDT) candidate, MP0712. Targeting DLL3, MP0712 features 212Pb as a potent therapeutic payload and demonstrates a strong tumor to kidney ratio, favorable biodistribution, antitumor activity, and a good safety profile in preclinical trials.

Presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2024 Annual Meeting, MP0712 aims to treat small-cell lung cancer (SCLC) and other DLL3+ neuroendocrine tumors. A first-in-human study is planned with initial data expected in 2025.

Molecular Partners' RDT platform is expanding to include additional targets, leveraging DARPins' unique properties like high affinity, selectivity, and small size. These advancements address historical challenges in radiopharmaceutical therapeutics, including kidney accumulation and suboptimal tumor uptake.

Molecular Partners has presented the final data from its Phase 1 trial of MP0317, a CD40 agonist, at the ASCO 2024 Annual Meeting. The study included 46 patients with advanced solid tumors and showcased favorable safety and promising efficacy. MP0317 was shown to localize within the tumor microenvironment (TME), activating immune cells without systemic toxicities. The drug's safety profile was manageable, with common side effects being mild fatigue and infusion reactions. One patient exhibited an unconfirmed partial response, while 14 had stable disease. The findings encourage further clinical trials, particularly in combination therapies.

Molecular Partners (MOLN) reported its Q1 2024 results, highlighting advancements in its clinical pipeline.

Key updates include the ongoing Phase 1 trial of MP0533, with dose escalation progressing smoothly and showing promising safety and anti-tumor activity. The Radio-DARPin Therapy platform is advancing with IND-enabling studies set for 2024, and preclinical data to be presented at upcoming conferences.

The company also provided updates on its Switch-DARPin Platform and MP0317 program, both showing progress towards key milestones.

Financially, Molecular Partners has CHF 174.1 million in cash, with no debt, funding into 2026. Operating expenses are expected to be CHF 70-80 million for 2024.

Molecular Partners announced the publication of preclinical data supporting MP0533's unique mechanism of action for treating acute myeloid leukemia in Cancer Immunology Research. The data demonstrates preferential killing of AML cells while sparing healthy cells, T-cell activation, tumor regression, and cytokine release without systemic adverse effects. The publication supports the rationale for the clinical development of MP0533 as monotherapy and in combination with other drugs. The ongoing Phase 1/2a clinical study is progressing well, currently dosing patients in cohort 7.

Life Science Cares launched its first international chapter in Switzerland, aiming to reduce poverty and inequality in local communities. LSCS will engage with Swiss life science organizations and charitable groups to provide opportunities for those at risk, especially children. The initiative will be highlighted at the Swiss Biotech Day, showcasing partnerships with key industry players and offering ways for individuals to contribute to the cause.

Molecular Partners AG announced that all Board proposals were approved at the Annual General Meeting. Shareholders confirmed the approval of the annual review, financial statements, and compensation report. The net loss for 2023 was carried forward, increasing the loss carried forward position. Amendments to the articles of incorporation were approved, and all Board members were re-elected. KPMG AG Zurich was re-elected as the Group's auditors for 2024.

Molecular Partners AG announces the Annual General Meeting 2024 with key dates and agenda items, focusing on DARPin therapeutics development.

Molecular Partners AG reported positive initial data from the Phase 1/2a trial of MP0533 for patients with relapsed/refractory AML and AML/MDS, introduced the Switch-DARPin platform, and presented preclinical data supporting the Radio-DARPin Therapy platform. The company announced a strategic collaboration with Orano Med, updated data from the Phase 1 trial of MP0317, and highlighted financial results for 2023, showing a strong financial position and an optimistic outlook for 2024.